Home > Companies > VBI Vaccines Inc.

VBI Vaccines Inc.

vbivaccines.com

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac® is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

Cell and Gene Therapy

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

PROTECTIVE CLOTHING FOR LIFE SCIENCES INDUSTRY GLOBAL MARKET TO WITNESS GROWTH IN BIOTECHNOLOGY AND HEALTHCARE SPENDING BY 2028

Research And Markets | June 30, 2020

The "Global Protective Clothing Market for Life Sciences Industry 2019-2028" report has been added to ResearchAndMarkets.com's offering.The publisher predicts that the global market for protective clothing for life sciences industry would witness a CAGR of 6.26% over the forecast period 2019-2028.The growth of this market is primarily being driven by the growing demand for protective clothing from end-users. Additionally, the large investments in research & developm...

FRED HUTCH MANDATES REMOTE WORKING TO CURB COVID-19

FierceBiotech | March 06, 2020

The Fred Hutchinson Cancer Research Center is making its Seattle-based staff work from home in light of the emergence of a cluster of coronavirus cases in the city. The precautionary action comes as biopharma companies are starting to pull back from face-to-face events to cut the risk of their employees catching the virus. As of Thursday, all of Fred Hutch’s Seattle-based employees, bar security and other staff that need to be on campus, are working remotely. Fred Hutch plans to keep the m...

PHARMACYTE BIOTECH ANNOUNCES IND SUBMITTED TO U.S. FDA FOR CLINICAL TRIAL IN LOCALLY ADVANCED, INOPERABLE PANCREATIC CANCER

PharmaCyte Biotech | September 02, 2020

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...

Cell and Gene Therapy